DKCM
VIGL

Davidson Kempner Capital Management’s Vigil Neuroscience VIGL Stock Holding History

Davidson Kempner Capital Management’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30,000
Closed -$211K – 607
2022
Q1 		$211K Buy
+30,000
New +$396K ﹤0.01% 390

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Davidson Kempner Capital Management's VIGL Position: Q2 2022 in Review

Davidson Kempner Capital Management sold out of Vigil Neuroscience (VIGL) in Q2 2022, closing a stake of 30,000 shares — an estimated $211K sold.

Davidson Kempner Capital Management first reported a position in VIGL in Q1 2022 and held it in 1 quarter. The position peaked at $211K in Q1 2022. 35 funds tracked by Wall St. Rank hold VIGL as of Q2 2022.

  • Davidson Kempner Capital Management reported no remaining Vigil Neuroscience position as of Q2 2022 after selling out during the quarter.
  • Davidson Kempner Capital Management sold 30,000 Vigil Neuroscience shares in Q2 2022, an estimated $211K.
  • Davidson Kempner Capital Management first reported a position in Vigil Neuroscience in Q1 2022 and held it in 1 quarter.
  • Davidson Kempner Capital Management's Vigil Neuroscience position peaked at $211K in Q1 2022.
  • 35 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q2 2022.

Based on Davidson Kempner Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.